Entries by

Mission and AbbVie Collaboration in Alzheimer’s and Parkinson’s Diseases Reaches Next Milestone

Mission receives $20 million milestone payment CAMBRIDGE, UK – 9 August 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on targeting the ubiquitin pathway, and AbbVie (“AbbVie”)(NYSE: ABBV) today announced progression of selected deubiquitylating enzyme (DUB) targets into the next phase of research in their neurodegenerative disease collaboration. In the second […]

Mission Therapeutics to present at Solebury Trout, Venrock and Oppenheimer’s EU Summer Investor Tour

CAMBRIDGE, UK – 13 July 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that its CEO, Anker Lundemose, will be presenting at the 5th annual EU Investor Tour hosted by Solebury Trout, Venrock, and Oppenheimer on 13-14 July. Anker will discuss the Company’s […]

Mission Therapeutics Invited to Present at UBS Innovation Series: The Next Wave in Neurodegeneration

CAMBRIDGE, UK – 2 June 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced today that Paul Thompson, Chief Scientific Officer (CSO), will present at the upcoming Next Wave in Neurodegeneration Investor event (3 June), as part of the UBS Innovation Series. Paul will […]

Mission Therapeutics to Attend and Present at Bio€quity Europe Digital 2021

CAMBRIDGE, UK– 14 May 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced that management team members will be attending and presenting at Bio€quity Europe (17-19 May). Anker Lundemose, CEO, David Luther, CFO, and Paul Wallace, CBO, will attend the digital event and will […]

Mission Therapeutics to Present at the Mitochondria-Targeted Drug Development Summit

CAMBRIDGE, UK– 26 April 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced today that Paul Thompson, Chief Scientific Officer, will present at the Mitochondria-Targeted Drug Development Digital Summit (27-29 April). Paul will present a seminar titled: USP30 Inhibitors: Releasing the Brakes to Improve […]

Mission Therapeutics to Participate in Upcoming SVB Leerink Biopharma Private Company Connect Event

CAMBRIDGE, UK– 22 April 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announced that members of its management will be attending the upcoming SVB Leerink Biopharma Private Company Connect Event. The event, which will take place virtually on 6-7 May 2021, is intended to […]

Mission Therapeutics Nominates First Development Candidates Targeting USP30

CAMBRIDGE, UK– 25 March 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has nominated the first two development candidates from its in-house USP30 inhibitor program. USP30 inhibitor candidates MTX652 and MTX114 will be advanced through preclinical good laboratory practice (GLP) toxicology studies during 2021, with […]

Mission Therapeutics Welcomes Co-founder of Rosetta Capital, Jonathan Hepple, to its Board of Directors

• Appointment follows Rosetta Capital acquisition of shareholding in Mission from Schroder Adveq CAMBRIDGE, UK– 24 March 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announces the appointment of Jonathan Hepple to the Company’s Board as a Non-Executive Director. Jonathan is joining Mission’s Board […]

Mission Therapeutics CSO to Present at the Targeted Protein Degradation Europe Summit

CAMBRIDGE, UK– 15 March 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), has announced today that Paul Thompson, Chief Scientific Officer, will present at the Targeted Protein Degradation Europe Summit (16-18 March). Paul Thompson will present on 18 March at 14:05 GMT, discussing how deubiquitylating […]

Mission Therapeutics CEO to Present at the Sachs Annual European Life Sciences CEO Forum

CAMBRIDGE, UK– 9 March 2021 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), announced today that Dr Anker Lundemose, CEO, will present at Sachs’ 14th Annual European Life Sciences CEO Forum. Anker Lundemose will present as part of a panel on 11 March at 15:10 CET […]